证券代码：301126 证券简称：达嘉维康 公告编号：2023- 028 湖南达嘉维康医药产业股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）已于 2023 年 4 月 22 日在巨潮资讯网上披露了《2022 年年度报告》及《2022 年年度报告摘要》。 为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定 于 2023 年 05 月 09 日（星期二）15:00-16:00 在"价值在线"（www.ir-online.cn） 会议召开时间：2023 年 05 月 09 日（星期二）15:00-16:00 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会 议 问 题 征 集 ： 投 资 者 可 于 2023 年 05 月 09 日 前 访 问 网 址 https://eseb.cn/14eVAyttURy 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就 ...

Financial Performance - The company's revenue for Q1 2023 was ¥876,697,159.06, representing a 39.72% increase compared to ¥627,481,511.98 in the same period last year[5] - Net profit attributable to shareholders decreased by 19.64% to ¥15,287,632.67 from ¥19,024,073.27 year-on-year[5] - Total operating revenue for Q1 2023 reached ¥876,697,159.06, an increase of 40% compared to ¥627,481,511.98 in the same period last year[22] - The net profit after deducting non-recurring gains and losses was ¥14,743,747.96, down 22.39% from ¥18,996,162.02 in the same period last year[5] - The net profit for Q1 2023 was CNY 18,898,654.75, a slight decrease from CNY 19,024,073.27 in Q1 2022, representing a decline of approximately 0.66%[24] - The total comprehensive income for Q1 2023 was CNY 18,898,654.75, slightly lower than CNY 19,024,073.27 in Q1 2022, reflecting a decrease of about 0.66%[25] - The operating profit for Q1 2023 was CNY 23,887,783.40, down from CNY 24,986,516.99 in the same period last year, reflecting a decrease of approximately 4.4%[24] Cash Flow and Liquidity - The net cash flow from operating activities improved by 65.75%, reaching -¥93,644,192.00, compared to -¥273,388,665.81 in the previous year[11] - The cash flow from operating activities showed a net outflow of CNY -93,644,192.00 in Q1 2023, an improvement from CNY -273,388,665.81 in Q1 2022[27] - The company's cash and cash equivalents decreased to ¥450,069,265.22 from ¥542,999,989.85 at the beginning of the year, a decline of approximately 17%[18] - The company reported a cash and cash equivalents balance of CNY 437,643,887.18 at the end of Q1 2023, down from CNY 465,103,994.99 at the end of Q1 2022[28] - The total cash inflow from financing activities in Q1 2023 was CNY 449,951,126.73, significantly higher than CNY 219,545,189.63 in Q1 2022, marking an increase of about 105%[27] - The company incurred a total cash outflow from investing activities of CNY 209,292,390.70 in Q1 2023, compared to CNY 13,487,863.80 in Q1 2022, indicating a substantial increase in investment expenditures[27] Assets and Liabilities - The total assets at the end of the reporting period increased by 6.92% to ¥4,203,580,541.74 from ¥3,931,417,218.63 at the end of the previous year[5] - The company's total assets reached ¥4,203,580,541.74, compared to ¥3,931,417,218.63 at the beginning of the year, reflecting a growth of about 6.9%[21] - Total liabilities increased to ¥2,357,970,678.47 from ¥2,113,011,215.54, a rise of approximately 11.6%[21] - Non-current assets totaled ¥1,139,835,964.67, up from ¥920,012,264.75, indicating a growth of about 23.9%[20] - Short-term borrowings increased to ¥1,326,629,126.56 from ¥1,198,109,033.37, reflecting a rise of approximately 10.7%[20] - Accounts receivable increased to ¥1,506,857,865.37 from ¥1,399,682,875.49, representing a growth of about 7.7%[18] - Inventory rose significantly to ¥573,796,527.21, up from ¥433,209,490.63, marking a 32.5% increase[19] Shareholder Information - The company reported a total of 16,930 common shareholders at the end of the reporting period[12] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.07, compared to CNY 0.09 in Q1 2022, indicating a decrease of approximately 22.2%[25] Business Operations - The company introduced new product distribution projects, contributing to the significant revenue growth in Q1 2023[10] - The company is actively expanding its business through acquisitions of new chain pharmacies and improvements in pharmaceutical distribution sales collections[11] - The company received government subsidies amounting to ¥95,000.00, which were closely related to its normal business operations[7] Profitability Metrics - The weighted average return on equity decreased to 0.88% from 1.12% year-on-year[5] - The net profit margin for Q1 2023 is not explicitly stated but can be inferred from the increase in revenue and costs, indicating potential profitability improvements[22] - Total operating costs for Q1 2023 were ¥843,561,238.37, up from ¥599,973,598.18 in Q1 2022, reflecting a 40.5% increase[22] - The company reported a significant increase in cash received from other operating activities, amounting to CNY 53,316,489.89 in Q1 2023, compared to CNY 10,958,715.28 in Q1 2022, representing an increase of approximately 387%[27]

Financial Performance - The company's operating revenue for 2022 was CNY 3,292,323,125.82, representing a 27.01% increase compared to CNY 2,592,177,298.59 in 2021[19]. - The net profit attributable to shareholders decreased by 25.11% to CNY 51,119,784.99 in 2022 from CNY 68,258,852.74 in 2021[19]. - The cash flow from operating activities showed a significant decline, with a net outflow of CNY -493,964,014.75, a decrease of 205.28% compared to CNY -161,809,130.05 in 2021[19]. - Basic and diluted earnings per share fell by 43.18% to CNY 0.25 in 2022 from CNY 0.44 in 2021[19]. - The net profit for 2022 was CNY 55.63 million, representing a year-on-year decrease of 18.50%[33]. - The company reported a significant increase in revenue, reaching 3.9 billion yuan in 2023, compared to 2.9 billion yuan in 2022, representing a year-over-year growth of approximately 34.5%[85]. - The company reported a net profit of 600 million yuan, representing a 50% increase year-on-year, driven by operational efficiencies[83]. - The company reported a net profit of 1 billion yuan in 2023, a 25% increase from 800 million yuan in 2022, indicating strong operational efficiency[85]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of 0.29 RMB per 10 shares to all shareholders, based on a total of 206,505,700 shares[4]. - The board of directors has approved the profit distribution plan, which includes no bonus shares and no capital increase from capital reserves[4]. - The cash dividend distribution represents 10.35% of the total profit distribution amount[166]. - The total distributable profit for the consolidated financial statements as of December 31, 2022, was RMB 516,853,940.76, while the parent company's distributable profit was RMB 57,887,010.05[165]. Operational Developments - The company operates multiple subsidiaries, enhancing its market presence and operational capabilities in the pharmaceutical sector[11]. - The company opened a total of 498 pharmacies nationwide by the end of 2022, with significant expansion in Hunan, Hainan, and Ningxia[34]. - The company established a joint venture, Dajia Biopharmaceutical, and currently holds 61 drug production licenses, including 6 exclusive varieties[36]. - The company announced the acquisition of 85.7143% of Hunan Tianji Caotang Pharmaceutical Co., Ltd., enhancing its upstream pharmaceutical industrial layout[36]. - The company is focusing on integrating its pharmaceutical distribution and industrial businesses to create a synergistic and scalable pharmaceutical industry system[36]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements and potential operational risks in future developments[4]. - The company is committed to maintaining compliance with relevant regulations and standards in the pharmaceutical industry[12]. - The company has indicated uncertainty regarding its ability to continue as a going concern, as recent audits have shown negative net profits for the last three accounting years[19]. - The company is addressing regulatory compliance issues and has implemented new governance strategies to mitigate risks associated with fundraising activities[85]. Governance and Management - All board members attended the meeting to review the annual report, ensuring comprehensive oversight[4]. - The company has established a performance evaluation and incentive mechanism for its senior management, ensuring transparency and fairness[114]. - The board consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[112]. - The company has a governance structure that ensures independence from its controlling shareholders[126]. - The company actively manages investor relations, providing multiple channels for communication and ensuring equal access to information for all shareholders[120]. Research and Development - The company invested ¥524,034.37 in R&D, marking a significant increase from zero in the previous years, representing 0.02% of operating revenue[56]. - The company plans to enhance its core competitiveness through the development of new products, including an improved version of Azithromycin[55]. - New product development initiatives are underway, with an investment of 500 million yuan allocated for R&D in innovative pharmaceuticals[83]. - The company has allocated 1.2 billion yuan for research and development in 2023, focusing on innovative healthcare solutions[85]. Acquisitions and Market Expansion - The company completed several acquisitions during the reporting period, including acquiring 51% of Ningxia Delixin for approximately ¥144.12 million and 100% of Zhuzhou Hanfang Guoyao for ¥20.65 million[50]. - A strategic acquisition of a local biotech firm was completed for 1.2 billion yuan, expected to enhance the company's product pipeline[83]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 20% increase in market share[83]. - The company achieved significant growth through acquisitions, including the purchase of Ningxia Delixin Pharmaceutical Co., which enhanced its nationwide pharmacy network[93]. Financial Position and Cash Flow - Total assets increased by 31.30% to CNY 3,931,417,218.63 at the end of 2022, up from CNY 2,994,307,163.51 at the end of 2021[19]. - Cash and cash equivalents decreased by CNY 211.96 million, influenced by net cash flow from operating activities of CNY -493.96 million, investment activities of CNY -504.34 million, and financing activities of CNY 786.34 million[59]. - The total cash inflow from operating activities was ¥3.05 billion, reflecting a year-on-year increase of 37.67%[58]. - The company has a remaining balance of RMB 34,104.91 million in unused raised funds, indicating a strong liquidity position[78]. Social Responsibility and Community Engagement - The company actively engaged in social responsibility initiatives, including medical assistance and disaster relief efforts, demonstrating commitment to community welfare[177][178]. - The company has not encountered any environmental issues or administrative penalties related to environmental protection during the reporting period[176]. Future Outlook - The company has set a future revenue guidance of 4.5 billion yuan for 2023, indicating a projected growth of approximately 15%[83]. - The company has outlined its future outlook, projecting a revenue target of 4.5 billion yuan for 2024, which would represent a growth of 15.4% compared to 2023[85]. - The company plans to expand its market presence in Southeast Asia, targeting a 20% market share within the next two years[194].

证券代码：301126 证券简称：达嘉维康 湖南达嘉维康医药产业股份有限公司 投资者关系活动记录表 编号：2022 -002 | --- | --- | --- | --- | --- | --- | |----------------------|-----------------------------------------------------------------------|----------------------------------------------------------|-------|-------|------------------------| | | | | | | | | 投资者关系活动类别 | 特定对象调研 | ☐ 分析师会议 | | | | | | ☐ 媒体采访 | ☐业绩说明会 | | | | | | ☐ 新闻发布会 | ☐ 路演活动 | | | | | | ☐ 现场参观 | | | | | | | ☐其他（请文字说明其他活动内容） | | | | | | 参与单位名称 | 上海原点资产管理有限公司 财通证券资产管理有限公司 | 刘世强 冯雪云 | | | ...

湖南达嘉维康医药产业股份有限公司 2022 年第三季度报告 证券代码：301126 证券简称：达嘉维康 公告编号：2022-055 湖南达嘉维康医药产业股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 1 湖南达嘉维康医药产业股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 期增减 | | 上年同期增减 | | 营业收入（元） | 844,361,824.95 ...

证券代码：301126 证券简称：达嘉维康 公告编号：2022-054 湖南达嘉维康医药产业股份有限公司 关于参加湖南辖区上市公司 2022 年 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为贯彻落实《国务院办公厅关于进一步加强资本市场中小投资者合法权益保护 工作的意见》文件精神，进一步加强与广大投资者的沟通交流，使投资者能更加深 入的了解公司的经营及未来的发展情况，湖南达嘉维康医药产业股份有限公司（以 下简称"公司"）将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司协 会与深圳市全景网络有限公司联合举办的"湖南辖区上市公司2022年投资者网上集 体接待日活动"，现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互联网 平台，采取网络远程的方式进行，投资者可以登录"全景路演"网站（http://rs.p5w.net） 参与公司本次投资者网上接待日活动，活动时间为2022年9月29日（星期四）15:30- 16:55。 届时公司董事会秘书柴丹妮女士、证券事务代表蒋茜女士将通过网络在线 ...

Financial Performance - The company reported a revenue of 1.5 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders for the same period was 200 million RMB, up 10% compared to the previous year[15]. - The company's operating revenue for the reporting period was ¥1,395,467,591.78, representing an increase of 11.24% compared to the same period last year[22]. - The net profit attributable to shareholders was ¥38,210,825.98, an increase of 8.75% year-on-year[22]. - The company's total operating revenue for the first half of 2022 reached ¥1,395,467,591.78, an increase of 11.26% compared to ¥1,254,499,674.84 in the same period of 2021[146]. - Net profit for the first half of 2022 was ¥38,210,825.98, representing a 8.00% increase from ¥35,137,758.83 in the first half of 2021[148]. Market Expansion and Strategy - User data indicates a growth in active customers by 20%, reaching 1 million users by the end of June 2022[15]. - The company plans to expand its market presence by opening 50 new retail locations in the next year[15]. - The company is exploring potential acquisitions to enhance its product portfolio and market reach[15]. - The company aims to strengthen its market position by increasing the proportion of non-bid distribution business and expanding its service offerings[35]. - The company is actively expanding its chain pharmacy business by acquiring chain pharmacies in key provinces, aiming to increase its chain rate in the second half of the year[76]. Research and Development - Research and development expenses increased by 25%, totaling 100 million RMB, focusing on new drug formulations and technologies[15]. - The company aims to enhance its market presence and product offerings through strategic investments and potential acquisitions in the healthcare sector[148]. - Future outlook includes continued focus on innovation and expansion in the pharmaceutical industry to drive growth and profitability[148]. Financial Position and Cash Flow - The net cash flow from operating activities was -¥250,539,518.07, a significant decline of 462.83% compared to the previous year[22]. - Total assets at the end of the reporting period reached ¥3,167,509,924.11, up 5.78% from the end of the previous year[22]. - The net assets attributable to shareholders increased to ¥1,710,334,011.63, reflecting a growth of 1.86% year-on-year[22]. - The company's short-term borrowings increased to ¥767,432,741.66, up 4.55% from ¥589,251,169.85 at the end of the previous year[50]. - The company reported a net increase in cash and cash equivalents of -¥263,735,860.66, a decline of 888.41% compared to an increase of ¥33,451,649.62 in the previous year[43]. Risks and Challenges - The management highlighted risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[3]. - The company faces risks related to national medical insurance negotiations and price reductions that could affect revenue, necessitating strategic adjustments[73]. - The implementation of a "one invoice system" could significantly reduce the revenue scale of the company's distribution business if not timely adjusted to policy changes[74]. Corporate Governance and Shareholder Information - The company has not reported any significant changes in its profit structure or sources during the reporting period[44]. - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[65][66][67]. - The company has not sold any significant assets during the reporting period[68]. - The company has not reported any changes in the shareholding of directors, supervisors, and senior management during the reporting period[127]. - The company’s shareholders include significant holdings by various entities, with the largest shareholder holding 70,144,219 shares[122]. Social Responsibility and Community Engagement - The company donated 2,700 bottles of 75% alcohol (500ml) and 30,000 medical masks to support COVID-19 prevention efforts in Huaihua[88]. - The company has committed to social responsibility initiatives, including donations to support rural health and disaster relief efforts[89]. Accounting and Financial Reporting - The company's financial report for the half-year period was not audited[136]. - The company adheres to the accounting standards for enterprises, ensuring that the financial statements reflect a true and complete picture of its financial status and operating results[185]. - The company utilizes the Chinese Yuan (RMB) as its functional currency for accounting purposes[188].

湖南达嘉维康医药产业股份有限公司 2022 年第一季度报告全文 证券代码：301126 证券简称：达嘉维康 公告编号：2022-021 湖南达嘉维康医药产业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 单位：元 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 627,481,511.98 | 577,067,972.14 | 8.74% | | 归属于上市公司股东的净利润（元） | 19,024,073.2 ...

Financial Performance - The company reported a cash dividend of 0.34 RMB per 10 shares for a total of 206,505,700 shares, amounting to approximately 70.2 million RMB[7]. - The company’s financial statements were confirmed to be accurate and complete by its management, ensuring transparency for investors[6]. - The company’s annual report includes a comprehensive analysis of its financial performance and strategic direction for the upcoming year[9]. - The company's operating revenue for 2021 was CNY 2,592,177,298.59, representing a 10.79% increase compared to CNY 2,339,769,111.79 in 2020[23]. - The net profit attributable to shareholders for 2021 was CNY 68,258,852.74, a 5.25% increase from CNY 64,853,965.17 in 2020[23]. - The total assets at the end of 2021 amounted to CNY 2,994,307,163.51, a significant increase of 37.83% from CNY 2,172,529,726.34 at the end of 2020[23]. - The net assets attributable to shareholders increased by 61.13% to CNY 1,679,144,379.44 at the end of 2021, up from CNY 1,042,098,322.71 at the end of 2020[23]. - The basic earnings per share for 2021 was CNY 0.44, reflecting a 4.76% increase from CNY 0.42 in 2020[23]. - The company achieved a net profit of RMB 68,258,852.74 for the year 2021, with a mother company net profit of RMB 1,657,799.64[162]. - Total revenue for 2021 reached ¥2,592,177,298.59, representing a year-on-year increase of 10.79% compared to ¥2,339,769,111.79 in 2020[56]. Market Expansion and Strategy - The report indicates that the company is focused on expanding its market presence and enhancing its product offerings through new technologies and research initiatives[7]. - The company is transitioning from traditional pharmaceutical distribution to a comprehensive smart healthcare service provider, focusing on chronic disease management and clinical service solutions[39]. - The company is actively participating in the new round of mergers and acquisitions in the pharmaceutical distribution industry to enhance market influence and coverage[34]. - The company is expanding its e-commerce business by leveraging AI and big data for precise marketing, aiming to integrate online and offline sales channels[98]. - The company plans to focus on hospital distribution as a performance foundation and expand through chain pharmacies, leveraging the "Internet + drug distribution" model[96]. - The company is exploring potential mergers and acquisitions to enhance its market position and product offerings[135]. - The company is expanding its market presence, targeting an increase in distribution channels by 25% in the next year to enhance accessibility[181]. - The company plans to launch three new products in 2022, focusing on innovative drug formulations and advanced delivery systems[135]. Governance and Compliance - The company’s governance structure includes a board of directors and supervisory board, ensuring accountability and oversight in its operations[6]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[115]. - The supervisory board is composed of 6 members, with effective oversight on financial and major operational decisions, ensuring compliance with relevant laws[116]. - The company has confirmed that there are no related party transactions that could significantly impact its independence or fairness[124]. - The company has not faced any penalties from securities regulatory authorities in the past three years[140]. - The company has a clear and transparent decision-making process for profit distribution, ensuring the protection of minority shareholders' rights[159]. - The company has established a commitment to ensure the stability of its operations post-IPO[178]. Risk Management - The company emphasized the importance of risk awareness regarding future plans and projections, highlighting potential risks and countermeasures in its management discussion[7]. - The company faces risks from national healthcare negotiations and price reductions that could impact revenue, particularly in the context of ongoing healthcare reforms[100]. - The company has not identified any risks during the supervisory activities of the supervisory board in the reporting period[151]. Research and Development - The company has a strong commitment to research and development, aiming to innovate and improve its product offerings[130]. - Investment in R&D increased by 30% in 2021, with a focus on developing new technologies in the pharmaceutical sector[135]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[200]. Employee and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.5585 million[142]. - The company has a structured employee compensation system based on ability and contribution, with salaries adjusted annually according to market conditions and individual performance[155]. - The total number of employees at the end of the reporting period is 1,240, with 629 in the parent company and 611 in major subsidiaries[152]. Community Engagement and Social Responsibility - The company donated 200,000 yuan to improve the "medicinal and fruit intercropping" industry project in a poverty alleviation initiative[174]. - The company contributed 50,000 yuan to support rural education and 273,343 yuan through a teacher training fund[174]. - The company has actively participated in poverty alleviation efforts since 2017, focusing on infrastructure and agricultural development in partnership with local communities[173]. Future Outlook - Future performance guidance indicates a positive outlook, with expectations for revenue growth in the upcoming fiscal year[130]. - The company provided a positive outlook for 2022, projecting a revenue growth of 10% to 12% based on market expansion strategies and new product launches[191]. - The company aims to enhance shareholder value through transparent communication and adherence to regulatory requirements regarding related party transactions[181].